Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | April 03, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby CLAT | 125,493 |
Reported balance
After 2023-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-03 · Gift · Disposed 259 · Balance 125,493 |
| Common StockSEC Table I · non-derivative | Direct | 312,578 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 312,578 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,963 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 23,461 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,461 |
| Common StockSEC Table I · non-derivative | Indirectby trust for grandch | 3,609 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,609 F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. |
Filing footnotes · ownership attribution and instrument terms
F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2019 Filed Dec 18, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | OtherCommon Stock | 126 | $375.31 | $47,289.06 |
DisclosureSEC source: 0001237899-19-000039 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,200 F1 · price: Represents volume-weighted average price of sales of 126 shares of Company stock on December 16, 2019 at prices ranging from $375.31 to $375.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 16, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 33 | $379.14 | $12,511.62 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,485 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 33 shares of Company stock on December 13, 2019 at prices ranging from $379.06 to $379.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,602 | $378.38 | $1,362,924.76 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,518 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,602 shares of Company stock on December 13, 2019 at prices ranging from $378.07 to $378.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,732 | $377.47 | $2,163,658.04 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,120 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 5,732 shares of Company stock on December 13, 2019 at prices ranging from $377.01 to $377.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13,060 | $376.36 | $4,915,261.60 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,852 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 13,060 shares of Company stock on December 13, 2019 at prices ranging from $376.00 to $376.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21,910 | $375.55 | $8,228,300.50 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,912 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 21,910 shares of Company stock on December 13, 2019 at prices ranging from $375.02 to $375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,873 | $374.79 | $2,575,931.67 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,822 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 6,873 shares of Company stock on December 13, 2019 at prices ranging from $374.22 to $374.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 632 | $373.26 | $235,900.32 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,695 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 632 shares of Company stock on December 13, 2019 at prices ranging from $373.21 to $373.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 107,655 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · derivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,655 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 55,813 | $377.16 | $21,050,431.08 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,327 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 107,655 | $21.25 | $2,287,668.75 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantPerformance Stock Units · Derivative | 9,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · derivative · entry 16 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires not disclosed F12 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F12 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F12 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 22:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 29,177 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000037 · edgardoc.xml · derivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,177 Underlying: Common Stock · 29,177 shares Expires 2029-12-11 F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,517 | $366.63 | $1,656,067.71 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 15 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,485 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 4,517 shares of Company stock on November 25, 2019 at prices ranging from $366.07 to $366.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,269 | $365.25 | $1,194,002.25 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 14 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,002 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 3,269 shares of Company stock on November 25, 2019 at prices ranging from $365.02 to $365.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,755 | $364.55 | $1,368,885.25 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 13 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,271 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 3,755 shares of Company stock on November 25, 2019 at prices ranging from $364.04 to $364.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,605 | $363.53 | $1,310,525.65 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,026 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,605 shares of Company stock on November 25, 2019 at prices ranging from $363.00 to $363.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,284 | $362.61 | $828,201.24 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 11 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,631 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 2,284 shares of Company stock on November 25, 2019 at prices ranging from $362.02 to $362.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,492 | $361.46 | $900,758.32 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,915 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 2,492 shares of Company stock on November 25, 2019 at prices ranging from $361.06 to $361.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 592 | $360.37 | $213,339.04 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,407 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 592 shares of Company stock on November 25, 2019 at prices ranging from $360.01 to $360.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,479 | $359.46 | $531,641.34 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,999 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 1,479 shares of Company stock on November 25, 2019 at prices ranging from $359.05 to $359.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 156 | $358.92 | $55,991.52 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,478 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 156 shares of Company stock on November 25, 2019 at prices ranging from $358.68 to $358.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 25, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 22,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,634 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 46,138 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · derivative · entry 21 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,655 Underlying: Common Stock · 46,138 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,727 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 23,989 | $358.33 | $8,595,978.37 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,727 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 46,138 | $21.25 | $980,432.50 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 21, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 7,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,578 Read SEC document |
| November 14, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 40,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,824 Read SEC document |
| October 02, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 764 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 17 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 144,897 Read SEC document |
| July 02, 2019 Filed Nov 26, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000024 · edgardoc.xml · nonDerivative · entry 16 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 145,661 Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,792 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000016 · edgardoc.xml · derivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,793 Underlying: Common Stock · 153,792 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 80,164 | $313.64 | $25,142,636.96 |
DisclosureSEC source: 0001237899-19-000016 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,505 Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 153,792 | $21.25 | $3,268,080.00 |
DisclosureSEC source: 0001237899-19-000016 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed May 29, 2019 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000016 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 146,330 Read SEC document |
| January 03, 2019 Filed May 29, 2019 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 569 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000016 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 146,844 Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 36,273 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,273 Underlying: Common Stock · 36,273 shares Expires 2028-12-12 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $382.32 | $2,293.92 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,304 Read SEC document |
| November 16, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 16,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,877 Read SEC document |
| November 15, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 19,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,038 Read SEC document |
| November 13, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 37,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,240 Read SEC document |
| October 04, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 147,413 Read SEC document |
| August 29, 2018 Filed Dec 14, 2018 21:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000023 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,449 Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 210 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-18-000014 · edgardoc.xml · derivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,585 Underlying: Common Stock · 210 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 108 | $374.46 | $40,441.68 |
DisclosureSEC source: 0001237899-18-000014 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,949 Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 210 | $21.25 | $4,462.50 |
DisclosureSEC source: 0001237899-18-000014 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $371.29 | $111,387.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 10 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on July 10, 2018 at prices ranging from $371.28 to $371.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $370.17 | $37,017.00 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,147 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13,194 | $369.41 | $4,873,995.54 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 13,194 shares of Company stock on July 10, 2018 at prices ranging from $369.00 to $369.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,211 | $368.61 | $4,501,096.71 |
DisclosureSEC source: 0001708138-18-000013 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,441 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 12,211 shares of Company stock on July 10, 2018 at prices ranging from $368.01 to $368.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 10, 2018 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.